scholarly journals Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression

Author(s):  
Steven Pennybaker ◽  
Brian J. Roach ◽  
Susanna L. Fryer ◽  
Anusha Badathala ◽  
Art W. Wallace ◽  
...  
2020 ◽  
Vol 87 (9) ◽  
pp. S139
Author(s):  
Anusha Badathala ◽  
Steven Pennybaker ◽  
Brian Roach ◽  
Daniel Mathalon ◽  
Art Wallace ◽  
...  

Author(s):  
Vangelis George Kanellis ◽  
Ramila Varendran

Lithium is an effective first-line mood stabiliser for bipolar disorder, treatment-refractory depression and suicide prevention. Studies have demonstrated its ability to produce neuroprotective benefits. Despite this, Lithium can cause neurotoxicity, cardiotoxicity and endocrine derangement resulting in severe (and potentially permanent) side effects. Lithium toxicity can be precipitated by illness, salt restriction diets, dehydration, nephrogenic diabetes insipidus, impaired creatinine clearance, concomitant drugs. This is particularly true in older patients with altered pharmacodynamics and pharmacokinetics. We present a 52-year-old female who presented with prolonged signs of lithium toxicity post-diarrhoea. Lack of monitoring due to her nomadic life-style resulted in the combination of long-lasting neurotoxicity and thyroid dysfunction. Our patient displayed neurotoxicity that was not present on imaging. This highlights the importance of regular monitoring of renal function, lithium serum levels and neuro-endocrine function to reduce complications associated with lithium toxicity.


2010 ◽  
Vol 82 (6) ◽  
pp. 594-600 ◽  
Author(s):  
D. Christmas ◽  
M. S. Eljamel ◽  
S. Butler ◽  
H. Hazari ◽  
R. MacVicar ◽  
...  

2014 ◽  
Vol 36 (14) ◽  
pp. 1-5
Author(s):  
Purushottam B. Thapa ◽  
Faiza A. Khan ◽  
Erika Petersen ◽  
Sushma Thapa

2020 ◽  
Author(s):  
Lora Lee McClain ◽  
Patricia Shaw ◽  
Roisin Sabol ◽  
Anna Maria Chedia ◽  
Anna Maria Segretti ◽  
...  

2020 ◽  
Vol 98 (7) ◽  
pp. 1322-1334
Author(s):  
Lora Lee McClain ◽  
Patricia Shaw ◽  
Roisin Sabol ◽  
Anna Maria Chedia ◽  
Anna Maria Segretti ◽  
...  

2003 ◽  
Vol 27 (3) ◽  
pp. 93-95 ◽  
Author(s):  
Arwel Thomas ◽  
David Taylor

Aims and MethodPrescribing of venlafaxine in The South London and Maudsley NHS Trust was found to account for over 50% of the antidepressant costs, but only 15% of the prescriptions. There is evidence to suggest that higher doses of venlafaxine may be effective in treating treatment-refractory depression. We aimed to discover if higher doses of venlafaxine used in the trust were related to prior failure to respond to antidepressant treatment. Hospital in-patients being treated with venlafaxine during a 1-week period in October 2001 were identified and case notes were reviewed to determine patient demographic data and prior history of antidepressant therapy.ResultsThere were 38 patients identified as being prescribed venlafaxine (18 of whom had a primary diagnosis of depression). Twenty-five were classed as non-treatment-resistant and 13 were classed as treatment-resistant. Doses of venlafaxine were statistically significantly higher in patients considered treatment-resistant (245 mg v. 180 mg daily, P=0.03). All other recorded patient characteristics were similar.Clinical ImplicationsHigher doses of venlafaxine were prescribed to patients who were retrospectively defined as treatment-refractory. Further studies should address the reasons for this prescribing practice.


Sign in / Sign up

Export Citation Format

Share Document